Improvement of hepatic steatosis in type 2 diabetic patients treated with a combination of pioglitazone and insulin

被引：0
|
作者：
Zib, Ivana
Salas, Naomi
Raskin, Philip
Szczepaniak, Lidia S.
机构：
来源：
DIABETES | 2006年 / 55卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A18 / A18
页数：1
相关论文
共 50 条
  • [41] Study of insulin requirement in diabetic patients with type 2 treated with outpatient insulin pump
    Courreges, J. P.
    Donnet, J. P.
    Gouet, D.
    Jan, P.
    Amin, K.
    Clavel, S.
    Gabreau, T.
    Guerci, B.
    Cosson, E.
    Cirette, B.
    DIABETES & METABOLISM, 2012, 38 : A99 - A99
  • [42] Hepatic Fibrosis but Not Steatosis Is Associated with Diabetic Kidney Disease in Nonobese Patients with Type 2 Diabetes
    Seo, Da Hea
    Cho, Yongin
    Ahn, Seong Hee
    Hong, Seongbin
    Lee, Yong-Ho
    Choi, Youngju
    Huh, Byoung Wook
    Huh, Kap Bum
    Kim, So Hun
    DIABETES, 2020, 69
  • [43] Changes in adipokines in newly diagnosed type 2 diabetes patients treated with exenatide, insulin or pioglitazone
    Yang, Xubin
    Xu, Wen
    Zhu, Dalong
    Sun Zilin
    Guo, Lixin
    Yang, Tao
    Wu, Ge
    Shi, Lixin
    Li, Qifu
    Qiu, Lin
    Li, Qiang
    Guo, Xiaohui
    Luo, Zuojie
    Lu, Juming
    Shan, Zhongyan
    Yang, Wenying
    Ji, Qiuhe
    Yan, Li
    Li, Hong
    Yu, Xuefeng
    Li, Shaoqing
    Zhou, Zhiguang
    Lv, Xiaofeng
    Liang, Zhen
    Lin, Shaoda
    Zeng, Longyi
    Yan, Jinhua
    Ji, Linong
    Weng, Jianping
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2016, 32 (SUPP 2) : 17 - 18
  • [44] Increased insulin secretion and not insulin sensitivity determines glycemic control in type 2 diabetic patients treated with metformin, glyburide and the combination of both
    Gulias-Herrero, A
    Aguilar-Salinas, C
    Gómez-Pérez, F
    Rull, J
    DIABETES, 2001, 50 : A420 - A420
  • [45] Hepatic insulin resistance in obese non-diabetic subjects and in type 2 diabetic patients
    Paquot, N
    Scheen, AJ
    Dirlewanger, M
    Lefèbvre, PJ
    Tappy, L
    OBESITY RESEARCH, 2002, 10 (03): : 129 - 134
  • [46] Triple therapy with pioglitazone/exenatide/metformin prevents hepatic fibrosis and steatosis in type 2 diabetes
    Lavrynenko, O.
    Abdul-Ghani, M.
    Alatrach, M.
    Puckett, C.
    Adams, J.
    Cersosimo, E.
    Alkhouri, N.
    DeFronzo, R. A.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S66 - S67
  • [47] Differential action of pioglitazone and metformin on hepatic fat, substrate metabolism and perfusion in type 2 diabetic patients
    Rijzewijk, L. J.
    van der Meer, R. W.
    Lubberink, M.
    Lamb, H. J.
    Romijn, J. A.
    de Roos, A.
    Twisk, J. W.
    Heine, R. J.
    Lammertsma, A. A.
    Smit, J. W. A.
    Diamant, M.
    DIABETOLOGIA, 2009, 52 : S336 - S336
  • [48] The effect of pioglitazone (PIO) as monotherapy and in combination with other oral diabetic medication (OAM) on glycemic control and insulin resistance in patients with Type 2 diabetes
    Mayorov, A
    Shestakova, M
    Antsiferov, M
    Balabolkin, M
    Chugunova, L
    Shamkhalova, M
    Zaytseva, N
    Naumenkova, I
    Brevnova, N
    Dedov, I
    Tsibina, L
    DIABETOLOGIA, 2004, 47 : A356 - A356
  • [49] Synergistic Improvement in Insulin Resistance with a Combination of Fenofibrate and Rosiglitazone in Obese Type 2 Diabetic Mice
    Choi, Woon-Seok
    Lee, Jung-Jin
    Kim, Yohan
    Kim, In-Su
    Zhang, Wei-Yun
    Myung, Chang-Seon
    ARCHIVES OF PHARMACAL RESEARCH, 2011, 34 (04) : 615 - 624
  • [50] Synergistic improvement in insulin resistance with a combination of fenofibrate and rosiglitazone in obese type 2 diabetic mice
    Woon-Seok Choi
    Jung-Jin Lee
    Yohan Kim
    In-Su Kim
    Wei-Yun Zhang
    Chang-Seon Myung
    Archives of Pharmacal Research, 2011, 34
12345